

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/187,693	11/05/1998	AYA JAKOBOVITS	CELL 4.20 CIP2 CPA	3392
75	90 03/09/2004		EXAMINER	
JANE T. GUNNISON, ESQ. FISH & NEAVE 1251 AVENUE OF THE AMERICAS			HUYNH, PHUONG N	
			ART UNIT	PAPER NUMBER
NEW YORK, 1	NY 10020		1644 DATE MAILED: 03/09/200	4 L9

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	09/187,693	JAKOBOVITS ET A	L.
Advisory Action	Examiner	Art Unit	
	Phuong Huynh	1644	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 03 October 2003 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appearamentation (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applicable in a timely filed amendment whit all (with appeal fee); or (3) a time	ch places the appli	cation in
	EPLY [check either a) or b)]		
a) The period for reply expiresmonths from the mailing of the period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The dath have been filed is the date for purposes of determining the period of extensions of the calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moderned patent term adjustment. See 37 CFR 1.704(b).	risory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date on FILED WITHIN TWO MONTHS OF THI te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the latest the period for reply originally set in	r the final rejection. E FINAL REJECTION. 36(a) and the appropriate fee. The appropriate ex the final Office action; or	See MPEP e extension fee tension fee under (2) as set forth in
1. A Notice of Appeal was filed on <u>06 October 2003</u> . A 37 CFR 1.192(a), or any extension thereof (37 CF	Appellant's Brief must be filed w R 1.191(d)), to avoid dismissal	vithin the period set of the appeal.	forth in
2. The proposed amendment(s) will not be entered b	ecause:		·
(a) X they raise new issues that would require furth	er consideration and/or search ((see NOTE below);	
(b) they raise the issue of new matter (see Note I	below);		
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mat	erially reducing or	simplifying the
(d) they present additional claims without cancel	ling a corresponding number of	finally rejected clai	ms.
NOTE: See Continuation Sheet.			
3. Applicant's reply has overcome the following reject			•
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	l be allowable if submitted in a s	separate, timely file	d amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:	or reconsideration has been cons	sidered but does No	OT place the
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which we	ere newly
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w	t(s) a)⊠ will not be entered or t ould be rejected is provided bel	o) will be entered ow or appended.	and an
The status of the claim(s) is (or will be) as follows:	;		
Claim(s) allowed: None.			
Claim(s) objected to: None			
Claim(s) rejected: <u>1-7</u> .			
Claim(s) withdrawn from consideration: <i>None</i> .			
8. The drawing correction filed on is a) app	proved or b) disapproved by	the Examiner.	
9. Note the attached Information Disclosure Stateme			
10. Other:			

Continuation Sheet (PTOL-303) 09/187,693

•

Continuation of 2. NOTE: The proposed amendment to claims 1-4, and 7 "isolated human antibody that binds to human epidermal growth factor receptor" raises new issue that would require further consideration and search. Said phrase now changes the scope of the antibody. Further, the proposed amendment to the specification contains numerous changes. A substitute specification is required.

CHRISTINA CHAN

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600